

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

20. (Cancel)

21. (Currently Amended) A The monoclonal antibody according to claim 20 wherein said monoclonal antibody forms an immunological complex

(a) with a peptide YSSPG<sup>\*</sup>SPGT (SEQ ID NO 1) or YSSPG<sup>\*</sup>SPGT (SEQ ID NO 2), wherein said peptide is phosphorylated at a position marked with \*,

D2  
N/E  
(b) or with any other peptide forming an immunological complex with a monoclonal antibody, which forms a complex with peptide YSSPG<sup>\*</sup>SPGT (SEQ ID NO 1) or YSSPG<sup>\*</sup>SPGT (SEQ ID NO 2).

24. (Currently Amended) A hybridoma which secretes a monoclonal antibody, wherein said monoclonal antibody according to claim 20 forms an immunological complex

(a) with a peptide YSSPG<sup>\*</sup>SPGT (SEQ ID NO 1) or YSSPG<sup>\*</sup>SPGT (SEQ ID NO 2), wherein said peptide is phosphorylated at a position marked with \*,

(b) or with any other peptide forming an immunological complex with a monoclonal antibody, which forms a complex with peptide YSSPG<sup>\*</sup>SPGT (SEQ ID NO 1) or YSSPG<sup>\*</sup>SPGT (SEQ ID NO 2).

25 - 28 (Cancelled)

29. (Currently Amended) A kit comprising for the in-vitro diagnosis of one of the following diseases Alzheimer's disease, Down's syndrome, Pick's disease, SSPE and other

neurological disorders in which abnormally phosphorylated tau protein or paired helical filaments are implicated, the kit comprising:

(a) A first monoclonal antibody wherein said monoclonal antibody forms an immunological complex

(i) with a peptide YSSPGSPGT (SEQ ID NO 1) or YSSPGSPGT (SEQ ID NO 2), wherein said peptide is phosphorylated at a position marked with \*,

(ii) or with any other peptide forming an immunological complex with a monoclonal antibody, which forms a complex with peptide YSSPGSPGT (SEQ ID NO 1) or YSSPGSPGT (SEQ ID NO 2).

according to claim 20 deposited on a microplate;

(b) a buffer solution, a second antibody recognizing a different epitope from said first monoclonal antibody which is a monoclonal antibody recognizing an epitope of normal tau, or of abnormally phosphorylated tau protein or which is a polyclonal antibody of normal tau, or of abnormally phosphorylated tau; and

(c) a marker for specific tagging or coupling with said second antibody; appropriate buffer solutions for carrying out the immunological reaction between said first monoclonal antibody and a test sample and the second antibody and the marker.

30. (Currently Amended) A monoclonal antibody according to claim 21 20, wherein said monoclonal antibody forms an immunological complex with an epitope of the human abnormally phosphorylated tau protein comprising a phosphorylated serine.

31. (New) A kit according to claim 29 further comprising a second antibody recognizing a different epitope from said first monoclonal antibody, the second antibody being a monoclonal antibody protein or which is a polyclonal antibody of normal tau, or of abnormally phosphorylated tau protein or which is a polyclonal antibody of normal tau, or of abnormally phosphorylated tau.

N/E  
32. (New) The kit according to claim 29, further comprising a buffer solution for carrying out the immunological reaction between said first monoclonal antibody and test sample.

D2  
33. (New) The kit according to claim 31, further comprising a buffer solution for carrying out the immunological reaction between said first monoclonal antibody and a test sample and the second antibody and the marker.

---